↑ 疾患リストへ ← 戻る

 16. クロウ・深瀬症候群 [臨床試験数:10,薬物数:12(DrugBank:6),標的遺伝子数:4,標的パスウェイ数:66] 

Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02921893October 31, 201615 April 2019Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeIxazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromePlasmacytoma;POEMS SyndromeDrug: Dexamethasone;Drug: Ixazomib Citrate;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Questionnaire AdministrationMayo ClinicNational Cancer Institute (NCI)Recruiting18 YearsN/AAll34Phase 2United States
2JPRN-UMIN0000186602015/08/172 April 2019Japanese POEMS syndrome with thalidmaide trial for compassionate useCrow-Fukase(POEMS) syndromeFPF300 (thalidomide)100-300mg/day,at bedtime +Dexamethasone 20mg/day (day1-4)

Duration:until the approval of thalidomide for POEMT syndrome
Chiba University Graduate School of MedicineRecruiting20years-oldNot applicableMale and Female20Not selectedJapan
3JPRN-UMIN0000183852015/07/012 April 2019Phase II study of efficiency of peripheral blood stem cell harvest in POEMS syndrome patients with low-dose cyclophosphamide plus G-CSFPOEMS syndromeThis study is composed of the following two steps of therapy.
1)PBSC mobilization using low dose cyclophosphamide and G-CSF
2)autologous peripheral stem cell transplantation after high dose chemotherapy
Chiba University Hospital Department of HematologyNot Recruiting20years-old70years-oldMale and Female14Phase 2Japan
4NCT02193698July 20148 August 2016Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome TrialSingle Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) SyndromePOEMS SyndromeDrug: Lenalidomide+DexamethasoneChiba UniversityNot recruiting20 YearsN/ABoth5Phase 2Japan
5NCT01816620March 201416 December 2017Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromeAn Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS SyndromePOEMS SyndromeDrug: Lenalidomide, DexamethasonePeking Union Medical College HospitalCelgene CorporationNot recruiting18 YearsN/AAll41Phase 2China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01639898July 201215 July 2019POEMS Syndrome Treatment With LenalidomidePhase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.POEMS SyndromeDrug: Lenalidomide and dexamethasoneUniversity Hospital, LimogesMinistry of Health, France;Celgene CorporationNot recruiting18 YearsN/AAll51Phase 2France
7JPRN-JMA-IIA0008422/03/20122 April 2019Japanese POEMS Syndrome with Thalidomide TrialJapanese POEMS Syndrome with Thalidomide TrialCrow-Fukase (POEMS) syndromeIntervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL.J-POST Clinical Trial OfficeHokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima UniversityNot Recruiting>=20 YEARSNo LimitBOTH24Phase 3Japan
8JPRN-JMA-IIA0004613/09/20102 April 2019Japanese POEMS Syndrome with Thalidomide TrialThalidomide Treatment for Crow-Fukase (POEMS) Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Extension Phase to Evaluate the Long-term SafetyCrow-Fukase (POEMS)syndromeIntervention type:DRUG. Intervention1:FPF 300 (thalidomide), Dose form:CAPSULE, Route of administration:ORAL. Control intervention1:FPF300 (placebo), Dose form:CAPSULE, Route of administration:ORAL.J-POST Clinical Trial OfficeHokkaido University, Hokkaido Medical Center, Tohoku University, Chiba University, Saitama Medical University, Niigata University, Shinshu University, Nagoya University, Kinki University, Kobe City Medical Center General Hospital, Yamaguchi University, Kyushu University, Kagoshima UniversityNot Recruiting>=20 YEARSNo LimitBOTH24Phase 2-3Japan
9EUCTR2008-003202-33-IT15/09/200919 March 2012Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002POEMS SYNDROME
MedDRA version: 9.1 Level: SOC Classification code 10029205
Trade Name: REVLIMID*21CPS 25MG
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Lenalidomide
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
ISTITUTO CLINICO HUMANITASAuthorisedFemale: yes
Male: yes
Italy
10NCT00971685July 200919 February 2015The Treatment of Lenalidomide in Patients With POEMS SyndromeEvaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS SyndromePOEMS SyndromeDrug: Lenalidomide and dexamethasoneIstituto Clinico HumanitasRecruiting18 YearsN/ABoth16Phase 2Italy

先頭へ